Alexion Soars On Strong Q2 Soliris Sales
This article was originally published in The Pink Sheet Daily
Executive Summary
The biotech was able to raise its guidance for 2011 after it reported stronger than expected sales in the second quarter for its rare blood disease drug.
You may also be interested in...
With Trio Of 2011 Deals, Alexion Looks To Nearly Double R&D Spending In 2012
The biotech, which is enjoying growing sales of high-priced, ultra-orphan terminal complement inhibitor Soliris, also has a pipeline of four other clinical and preclinical candidates for rare diseases.
Alexion's Soliris Gains New Orphan Indication But Limited Sales Expectations
The devastating natural course of atypical hemolytic uremic syndrome, coupled with the small quantity of drug used to treat pediatric patients, means the new use is expected to have only a small impact on sales initially, Alexion's management says.
Alexion's Soliris Gains New Orphan Indication But Limited Sales Expectations
The devastating natural course of atypical hemolytic uremic syndrome, coupled with the small quantity of drug used to treat pediatric patients, means the new use is expected to have only a small impact on sales initially, Alexion's management says.